415 Capital

Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.

Endovascular Engineering is a preclinical stage company dedicated to advancing innovative mechanical thrombectomy solutions for peripheral medical conditions. The firm specializes in the development of clot removal technologies specifically designed to address venous thromboembolism, which encompasses critical health issues such as pulmonary embolism and deep vein thrombosis. By focusing on these areas, Endovascular Engineering aims to equip healthcare professionals with efficient and effective tools to enhance patient outcomes in the management of these vascular conditions.

R3 Vascular develops bioresorbable scaffold technology coated with sirolimus for treating peripheral arterial disease. Its proprietary polymer and technologies create scaffolds that balance strength and flexibility, with a thin strut thickness of 98 microns.

Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.

Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.

TRiCares is a medical device company focused on creating innovative solutions for tricuspid valve regurgitation. The company specializes in developing a catheter-based valve replacement system that facilitates minimally invasive treatments for patients suffering from tricuspid insufficiency. By emphasizing anatomical conformation and user-friendly design, TRiCares aims to provide effective and durable treatment options that improve patient outcomes. Through its advancements in medical technology, TRiCares addresses a critical need in cardiology, enhancing the quality of care for those affected by this condition.

Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.

Distalmotion, founded in Lausanne, Switzerland, is a medical device company dedicated to simplifying robotic surgery to enhance access to high-quality, minimally invasive care for patients in general surgery, gynecology, and urology. The company has developed a surgical robot named Dexter, which integrates the advantages of laparoscopy with those of robotics. Dexter offers an affordable solution by providing on-demand robotic surgery capabilities, combining cost-effectiveness with advanced surgical techniques.

Aktiia develops continuous, convenient, and medical-grade blood pressure monitoring enabled by wearable sensors and machine learning. Built on extensive research, it delivers continuous BP and heart rate data to patients, researchers, and clinicians, supporting personalized insights and new understandings of hypertension. The company aims to make blood pressure management more accessible, accurate, and actionable for people worldwide, addressing a condition that affects over a billion people and causes millions of deaths annually.

Cardiac Success develops medical devices aimed at improving cardiac function in patients with heart failure and related conditions. The company is behind implants intended to enhance cardiac output in those with heart failure and functional mitral regurgitation, and it has developed the V-sling, a transcatheter ventricular repair device based on a surgical papillary muscle approximation technique, designed to aid patients with heart failure with reduced ejection fraction.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions in patients experiencing heart attacks. The company has created a controlled flow infusion system that utilizes a proprietary concept to measure microvascular resistance, allowing interventional cardiologists to assess the severity of microvascular obstruction. By comparing these measurements with post-procedure contrast-enhanced magnetic resonance imaging, CorFlow's technology aims to improve the diagnosis and treatment of microvascular obstruction, potentially reducing both short- and long-term complications for severe heart attack patients. Through its advancements, CorFlow is committed to addressing significant unmet medical needs in cardiology.

Moray Medical is a company focused on developing innovative robotic delivery systems for structural heart therapies, specifically targeting edge-to-edge valve leaflet repair. The company aims to enhance the quality of life for millions affected by leaky heart valves by providing cardiologists with advanced tools for mitral valve clip therapies. Moray Medical's proprietary microfluidic robotics technology enables the precise and safe delivery of treatments, utilizing a compact, reusable fluid-drive system that features a digital interface for maneuvering flexible delivery catheters with ease, akin to using a computer cursor. This approach allows for cost-effective interventions, making life-saving heart valve therapies more accessible to a broader range of patients in need.

R3 Vascular develops bioresorbable scaffold technology coated with sirolimus for treating peripheral arterial disease. Its proprietary polymer and technologies create scaffolds that balance strength and flexibility, with a thin strut thickness of 98 microns.

Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.